Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-CIDEB in MASLD and MASH
NCT06836609Phase 2Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2025
- Primary completion
- Aug 2027
- Modality
- Lipid-based Nanoparticles, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 2
01
Overview
A Phase 2 trial of ALN-CIDEB in metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Regeneron Pharmaceuticals. Started Apr 2025; status: active, not recruiting.
02
Drugs
ALN-CIDEB
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT06836609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06836609.